In this Ophthalmology Times Peer Exchange, the expert faculty discussed the evolving management of retinal vascular diseases, including wet AMD, diabetic macular edema, diabetic retinopathy, and retinal vein occlusion. The panel reviewed the growing treatment burden associated with these conditions, advancements in retinal imaging and diagnostics, and the expanding role of next-generation anti-VEGF therapies in improving durability and disease control. Throughout the discussion, the panelists examined clinical trial and real-world data supporting newer agents such as aflibercept 8 mg and faricimab, while also highlighting challenges related to treatment burden, patient adherence, safety, and insurance access. The conversation concluded with insights into emerging therapies, including tyrosine kinase inhibitors and gene therapy, and how these innovations may further transform the future treatment landscape for retinal vascular diseases.